Expanding Treatment Access for RDEB Patients
Abeona Therapeutics Inc. (NASDAQ: ABEO) proudly announces the activation of The University of Texas Medical Branch (UTMB) as the latest Qualified Treatment Center for ZEVASKYN, a groundbreaking gene-modified cellular therapy aimed at treating wounds in individuals affected by recessive dystrophic epidermolysis bullosa (RDEB). This innovative therapy is FDA-approved and represents a significant advancement in wound care for both adults and children suffering from this condition.
UTMB: A Leader in Dermatology
UTMB has established itself as a leading academic center, particularly known for its pioneering dermatology department in Texas. The institution has a rich history of providing advanced care for complex skin diseases and wound management, making it an ideal site for administering ZEVASKYN.
Improving Patient Outcomes with ZEVASKYN
Dr. Madhav Vasanthavada, Chief Commercial Officer at Abeona, highlighted the importance of this partnership, stating, “The activation of UTMB as a QTC greatly enhances the access to ZEVASKYN for patients throughout Texas and the broader Gulf Coast.” This strategic collaboration not only extends patient access but also aligns with UTMB's commitment to delivering innovative treatments to those in need.
Understanding Recessive Dystrophic Epidermolysis Bullosa
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare and severe skin disorder characterized by chronic blistering and painful lesions that lead to significant complications over time. This condition arises from defects in the COL7A1 gene, which impairs the production of type VII collagen, essential for skin integrity. Patients often face a formidable burden due to the relentless nature of their symptoms and the challenges in wound care that require constant attention and management.
The Role of ZEVASKYN in Treatment
ZEVASKYN (prademagene zamikeracel) stands out as a unique therapy, utilizing autologous cell sheet-based approach to address the effects of RDEB. By integrating the functional COL7A1 gene into the patient's skin cells, ZEVASKYN has shown promising results in healing wounds and alleviating pain from a single surgical application.
Patient Support and Access
Abeona Therapeutics also emphasizes its commitment to patient care through the Abeona Assist program. This comprehensive support service provides eligible patients with assistance navigating insurance benefits, securing financial aid, and logistical help associated with accessing treatment. Patients and their families can take advantage of this resource to facilitate their journey and ensure they receive the care they need.
Innovations and Future Directions
Abeona stands at the forefront of developing cell and gene therapies not only for RDEB but also for other serious conditions. The company operates a state-of-the-art cGMP manufacturing facility in Cleveland, which is pivotal for producing ZEVASKYN for commercial distribution. Furthermore, Abeona is actively exploring adeno-associated virus (AAV)-based therapies targeting various diseases with high unmet needs, leveraging next-generation AAV capsids to enhance treatment efficacy.
Important Safety Information
Though ZEVASKYN offers remarkable healing potential, patients need to be aware of certain safety considerations. Serious allergic reactions can occur, necessitating prompt medical attention. Moreover, monitoring for potential long-term effects, such as cancer, is essential due to the nature of gene therapies. Common side effects include procedural pain and itching, but these should be discussed with a healthcare provider to ensure patient safety and comfort.
Frequently Asked Questions
What is ZEVASKYN?
ZEVASKYN (prademagene zamikeracel) is an FDA-approved gene-modified cellular therapy developed to treat wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).
How does ZEVASKYN work?
ZEVASKYN incorporates the COL7A1 gene into the patient's own skin cells, which helps in producing functional type VII collagen, essential for skin healing and integrity.
Where can I access ZEVASKYN treatment?
The University of Texas Medical Branch (UTMB) is a qualified treatment center for ZEVASKYN, enhancing access for patients in Texas and the Gulf Coast region.
What support services does Abeona provide?
Abeona Assist offers personalized support, including assistance with insurance, financial options, and logistical help for eligible patients seeking ZEVASKYN treatment.
What are the common side effects of ZEVASKYN?
Common side effects include pain at the treatment site and itching. Patients should consult their healthcare provider for advice on managing side effects.
